Cardio IQ® Apolipoprotein Evaluation

Cardio IQ® Apolipoprotein Evaluation

Test Code

91727
82172 (x2)
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
91727
82172 (x2)
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano | Quest Nichols Institute -San Juan Capistrano, CA. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection may be available in your area for purchase through Quest Mobile.

Clinical Significance

Cardio IQ® Apolipoprotein Evaluation - Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Test Resources

None found for this test
Please visit our Clinical Education Center to stay informed on any future publications, webinars, or other education opportunities.

Test Details

Includes

  • Apolipoprotein A1
  • Apolipoprotein B
  • Apolipoprotein B/A1 Ratio

Methodology

Immunoturbidimetric

Reference Range(s)

Apolipoprotein A1

Male≥115 mg/dL
Female≥125 mg/dL
Risk CategoryMaleFemale
Optimal≥115 mg/dL≥125 mg/dL
High<115 mg/dL<125 mg/dL
Cardiovascular event risk category cut points (optimal, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Apolipoprotein B<90 mg/dL
Risk Category
Optimal<90 mg/dL
Moderate90-129 mg/dL
High≥130 mg/dL
⁠⁠⁠⁠⁠⁠⁠A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based on AACE/ACE and ACC/AHA recommendations (Grundy SM, et al. 2019. doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490).

Apolipoprotein B/A1 Ratio
Male<0.77
Female<0.63
Risk CategoryMaleFemale
Optimal<0.77<0.63
Moderate0.77-0.950.63-0.78
High>0.95>0.78
Cardiovascular event risk category cut points (optimal, moderate, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Alternative Name(s)

CardioIQ®,Apolipoprotein Evaluation, Cardio IQ®

LOINC® Codes, Performing Laboratory

Service Area must be determined
Apolipoprotein A1
Apolipoprotein B
Apolipoprotein B/A1 Ratio

Methodology

Immunoturbidimetric

Reference Range(s)

Apolipoprotein A1
Male≥115 mg/dL
Female≥125 mg/dL
Risk CategoryMaleFemale
Optimal≥115 mg/dL≥125 mg/dL
High<115 mg/dL<125 mg/dL
Cardiovascular event risk category cut points (optimal, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Apolipoprotein B<90 mg/dL
Risk Category
Optimal<90 mg/dL
Moderate90-129 mg/dL
High≥130 mg/dL
⁠⁠⁠⁠⁠⁠⁠A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based on AACE/ACE and ACC/AHA recommendations (Grundy SM, et al. 2019. doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490).

Apolipoprotein B/A1 Ratio
Male<0.77
Female<0.63
Risk CategoryMaleFemale
Optimal<0.77<0.63
Moderate0.77-0.950.63-0.78
High>0.95>0.78
Cardiovascular event risk category cut points (optimal, moderate, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Alternative Name(s)

CardioIQ®,Apolipoprotein Evaluation, Cardio IQ®
Service Area must be determined

Preferred Specimen(s)

1 mL serum

Minimum Volume

0.5 mL

Transport Container

Transport tube

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

  • Room temperature: 7 days
    Refrigerated: 7 days
    Frozen: 30 days

Reject Criteria

Grossly lipemic

Setup Schedule

Service Area must be determined
1 mL serum
0.5 mL
Transport tube
Refrigerated (cold packs)
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 30 days
Grossly lipemic
Service Area must be determined
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano | Quest Nichols Institute -San Juan Capistrano, CA. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection may be available in your area for purchase through Quest Mobile.
Test Details

Clinical Significance

Test Resources

Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.

The CPT codes provided are based on AMA guidance and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

This material contains content from LOINC® (http://loinc.org). The LOINC Table, LOINC Table Core are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license.

The tests listed by specialty and category are a select group of tests offered. For a complete list of Quest Diagnostics tests, please adjust the filter options chosen, or refer to our Directory of Services.

Customize the test information for your Service Area